



## **Heron Therapeutics to Present at the Jefferies London Healthcare Conference**

November 8, 2017

SAN DIEGO--(BUSINESS WIRE)--Nov. 8, 2017-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Jefferies London Healthcare Conference on Thursday, November 16, 2017, at 4:00 p.m. GMT (11:00 a.m. EST).

A live webcast of this presentation and accompanying slides will be available on the Company's website at [www.heronrx.com](http://www.heronrx.com) in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

### **About Heron Therapeutics, Inc.**

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. For more information, visit [www.heronrx.com](http://www.heronrx.com).

### **Forward-Looking Statements**

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171108006355/en/>

Source: Heron Therapeutics, Inc.

### **Investor Relations and MediaContact:**

Heron Therapeutics, Inc.  
David Szekeres, 858-251-4447  
Senior VP, General Counsel, Business Development and Corporate Secretary  
[dszekeres@heronrx.com](mailto:dszekeres@heronrx.com)